SSRI耐药重性抑郁障碍患者来源神经元中血清素诱导的过度活跃
研究从SSRI缓解与未缓解的重性抑郁障碍(MDD)患者中制备诱导多能干细胞(iPSCs),并在体外研究前脑神经元的血清素能神经传递。未缓解患者来源神经元在SSRI治疗后表现出由上调的兴奋性血清素受体下游介导的血清素诱导过度活跃,而健康对照和缓解患者来源神经元无此表现。提示前脑突触后过度活跃可能参与SSRI耐药机制。
要点
- 未缓解MDD患者来源前脑神经元出现血清素诱导的过度活跃。
- 该过度活跃由上调的兴奋性血清素受体下游信号介导。
- 健康对照和SSRI缓解患者来源神经元无此表现。
核心结论
- SSRI治疗后的前脑突触后过度活跃可能参与MDD的SSRI耐药。
- 患者来源神经元可揭示与药物反应性相关的疾病神经表型。
研究设计与样本
- 从大型特征明确的MDD患者队列中,为SSRI缓解者和SSRI未缓解者制备诱导多能干细胞(iPSCs)。
- 在体外研究患者前脑神经元的血清素能神经传递。
主要发现
- 未缓解患者来源神经元表现出血清素诱导的过度活跃。
- 该过度活跃位于上调的兴奋性血清素受体下游。
- 健康对照和缓解患者来源神经元未见此表现。
关键数值与推荐
- 约30%的MDD患者观察到SSRI耐药。
临床怎么用
- 患者来源神经元模型可用于探索SSRI耐药的神经表型。
- 兴奋性血清素受体下游的突触后过度活跃可能成为SSRI耐药的相关靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed antidepressants. They regulate serotonergic neurotransmission, but it remains unclear how altered serotonergic neurotransmission may contribute to the SSRI resistance observed in approximately 30% of major depressive disorder (MDD) patients. Patient stratification based on pharmacological responsiveness and the use of patient-derived neurons may make possible the discovery of disease-relevant neural phenotypes. In our study from a large cohort of well-characterized MDD patients, we have generated induced pluripotent stem cells (iPSCs) from SSRI-remitters and SSRI-nonremitters. We studied serotonergic neurotransmission in patient forebrain neurons in vitro and observed that nonremitter patient-derived neurons displayed serotonin-induced hyperactivity downstream of upregulated excitatory serotonergic receptors, in contrast to what is seen in healthy and remitter patient-derived neurons. Our data suggest that postsynaptic forebrain hyperactivity downstream of SSRI treatment may play a role in SSRI resistance in MDD.
引用
- Vadodaria KC, Ji Y, Skime M, et al. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Mol Psychiatry. 2019. PMID: 30700803. doi:10.1038/s41380-019-0363-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。